Objective: The aim of this study was to determine if cranial electrotherapy stimulation (CES) is beneficial in chronically symptomatic bipolar (CSBP) subjects.
Dear Editor:
Subsyndromal symptoms are common in bipolar disorders. 1 Subsyndromal symptoms occupy 14.8% of the lives of type I bipolar patients and 15.7% of type II patients. 1 Anxiety disorder may co-occur with bipolar disorder in more than 90% of patients. 2 High rates of co-occurrence of personality disorders, substance abuse disorders, and attention deficit disorder are also notable. 2 These issues conspire to create a significant fraction of bipolar patients who are chronically or frequently symptomatic. These groups of patients are clinically challenging and frequently require extensive polypharmacy. Despite aggressive treatment, chronically symptomatic bipolar patients (CSBP) continue to exhibit cycling, mixed polarity, and subsyndromal symptoms.
Cranial electrotherapy stimulation (CES) was approved by the US Food and Drug Administration for treating anxiety, depression, and insomnia in 1979. Its use in CSBP has not been examined.
METHOD Design
This was a retrospective chart review of naturalistic use of CES in CSBPs. Chronically symptomatic bipolar patients have variable psychiatric symptoms that do not meet syndromal levels. These patients are not rapid cycling because they do not meet syndromal criteria but are chronically symptomatic. Seven consecutive patients met inclusion criteria of a diagnosis of bipolar type I or type II and chronic symptoms not responsive to ongoing medication. Data were collected for 8 weeks.
All patient used the AlphaStim SCS (Electromedical Products International, Inc, Mineral Wells, Tex). Each patient was instructed to set the current between 10 and 500 KA and a frequency of 0.5 Hz, with pulse duration of 2 milliseconds, for 1 or 2 daily sessions ranging from 20 to 60 minutes each. The electrical current was delivered by 2 surface wet electrodes that were clipped to both ear lobes.
Data collected from the charts included the Global Assessment of Function, Clinical Global Impression (CGI), the Montgomery Asberg Depression Rating Scale, and the Young Mania Scale.
Data Analysis
Differences were examined using paired t tests.
RESULTS
Five women and 2 men participated. The mean (SD) age was 42.3 (6.4) years. Four had type II illness, and 3 had type I. All patients were on anticonvulsant mood stabilizers or lithium and a second-generation antipsychotic. Most were also on other medications that addressed anxiety (gabapentin, propranolol, prazocin, or a benzodiazepine), sleep disturbance (trazadone, ropinirole), or attentional problems (methylphenidate). The mean number of psychotropic medications was 4.25 (compared with the overall clinic mean of 3.0 psychotropics). The patients titrated their duration and current strength to their perceived optimal level. Nearly always this corresponded to a setting of 4 (approximately 350 KA), for 30 minutes daily. Two patients used the maximum setting of 6 (approximately 500 KA), for 1 hour daily. Most patients varied the length of the sessions on a daily basis, usually in response to their level of distress on that particular day, so that an accurate duration could not be determined. Clinical Global Impression significantly decreased (Table 1) . Most measured variables also improved nonsignificantly ( Table 1 ). The effect size of the improvement in depressive symptoms was small 0.1. The power of the current study for capturing a difference of that effect is moderate at 0.48. A sample of approximately 20 patients would be required to show that the improvement is significant. There were very few adverse consequences. Four reported mild light-headedness or dizziness, which was not sufficient to discontinue treatment. Four subjects thought that the improvement was sufficient to warrant purchasing the device.
DISCUSSION
In this naturalistic retrospective chart review of CSBPs, the use of CES was associated with a small effect in symptom improvement. A significant improvement was seen in CGI, which improved nearly 25% (P G 0.001; Table 1 ). Depressive symptoms improved some 34%, and manic symptoms improved 21% (both not significant; Table 1 ). The lack of significant improvement in mood symptoms suggests that the CGI effect may have been driven by improvements in anxiety or other factors, which were not measured in these patients.
These results are in line with previously reported effects of CES. A survey in 2002 showed that 66% of patients with depression had greater than 50% improvement, and 31% of patients reported greater than 75% improvement. 3 More than 35% of patients with anxiety alone (n = 128) reported greater than 75% improvement, but only 29% of patients with both anxiety and depression (n = 58) had greater than 75% improvement. 3 However, survey studies may overestimate the efficacy of treatment modalities, the results are, nonetheless, important to consider.
Even with a small effect size, CES may be a reasonable intervention because it has very few adverse effects (AEs). 4 Adverse effects are uncommon, headache (0.20%) and local skin irritation (0.11%) are the more frequent but are generally mild. Other rare AEs include vertigo, dizziness, disorientation, seizures, nausea, and electrical skin burns at the site of the electrodes. Many of these AEs can be modified by reduction in treatment intensity. In our patients, AEs were very rare and mild.
The mechanism of CES is not known. It is believed that CES may stimulate the vagus nerve, causing a parasympathetic response and resultant relaxation. Much of the effect is believed to be mediated by brain stem nuclei that radiate widely through the central nervous system. 5 This includes all the systems believed to be important in mood and anxiety disorders (dopamine, serotonin, and norepinephrine). Cranial electrotherapy stimulation has been shown to increase synchronous activity on electroencephalogram. 
